文献速递瓣膜病与结构性心脏病

主动脉瓣置换术后心脏损伤与生活质量:PARTNER试验分析

Cardiac Damage and Quality of Life After Aortic Valve Replacement in the PARTNER Trials.
PubMed 文献 · J Am Coll Cardiol · 2023-01-01

该研究汇总PARTNER 2和3试验的1,974例患者,按基线及1年超声心动图心脏损伤分期(0-4期)分析。基线损伤程度越重,基线和1年KCCQ评分越低,1年不良结局率越高(0-4期分别为10.6%、19.6%、29.0%、44.7%、39.8%,P<0.0001);基线损伤每增加1期,不良结局风险增加24%(95%CI 9%-41%,P=0.001);1年损伤分期改善与KCCQ-OS改善程度相关(P<0.0001)。

要点

  • 基线心脏损伤分期越高,AVR前后健康状态越差、1年不良结局率越高。
  • 基线损伤每增加1期,1年不良结局风险增加24%(95%CI 9%-41%)。
  • AVR后1年损伤分期改善者KCCQ-OS提升更明显。

核心结论

  • AVR前心脏损伤程度对健康状态结局有重要影响,包括横断面及AVR后。

研究设计与样本

  • 汇总PARTNER 2和3试验患者,按基线及1年超声心动图心脏损伤分期(0-4期)分组分析。
  • 共纳入1,974例患者,其中外科AVR 794例,经导管AVR 1,180例。

主要发现

  • 基线心脏损伤程度与基线及AVR后1年KCCQ评分降低相关(P<0.0001)。
  • 1年不良结局(死亡、KCCQ-OS<60或KCCQ-OS下降≥10分)率0-4期分别为10.6%、19.6%、29.0%、44.7%、39.8%(P<0.0001)。
  • 多变量模型中,基线心脏损伤每增加1期,不良结局风险增加24%(95%CI 9%-41%,P=0.001)。
  • AVR后1年心脏损伤分期变化与同期KCCQ-OS改善程度相关:改善≥1期平均+26.8(95%CI 24.2-29.4),无变化+21.4(95%CI 20.0-22.7),恶化≥1期+17.5(95%CI 15.4-19.5)(P<0.0001)。

临床怎么用

  • 评估AVR候选者时,应关注超声心动图心脏损伤分期,以预判术后健康状态改善程度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The extent of extravalvular cardiac damage is associated with increased risk of adverse events among patients with severe aortic stenosis undergoing aortic valve replacement (AVR). OBJECTIVES: The goal was to describe the association of cardiac damage on health status before and after AVR. METHODS: Patients from the PARTNER (Placement of Aortic Transcatheter Valves) 2 and 3 trials were pooled and classified by echocardiographic cardiac damage stage at baseline and 1 year as previously described (stage 0-4). We examined the association between baseline cardiac damage and 1-year health status (assessed by the Kansas City Cardiomyopathy Questionnaire Overall Score [KCCQ-OS]). RESULTS: Among 1,974 patients (794 surgical AVR, 1,180 transcatheter AVR), the extent of cardiac damage at baseline was associated with lower KCCQ scores both at baseline and at 1 year after AVR (P < 0.0001) and with increased rates of a poor outcome (death, KCCQ-OS <60, or a decrease in KCCQ-OS of ≥10 points) at 1 year (stages 0-4: 10.6% vs 19.6% vs 29.0% vs 44.7% vs 39.8%; P < 0.0001). In a multivariable model, each 1-stage increase in baseline cardiac damage was associated with a 24% increase in the odds of a poor outcome (95% CI: 9%-41%; P = 0.001). Change in stage of cardiac damage at 1 year after AVR was associated with the extent of improvement in KCCQ-OS over the same period (mean change in 1-year KCCQ-OS: improvement of ≥1 stage +26.8 [95% CI: 24.2-29.4] vs no change +21.4 [95% CI: 20.0-22.7] vs deterioration of ≥1 stage +17.5 [95% CI: 15.4-19.5]; P < 0.0001). CONCLUSIONS: The extent of cardiac damage before AVR has an important impact on health status outcomes, both cross-sectionally and after AVR. (PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - XT Intermediate and High Risk (PII A), NCT01314313; The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves - PII B [PARTNERII B], NCT02184442; PARTNER 3 Trial: Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis [P3], NCT02675114).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Généreux P, Cohen DJ, Pibarot P, et al. Cardiac Damage and Quality of Life After Aortic Valve Replacement in the PARTNER Trials. J Am Coll Cardiol. 2023. PMID: 36813373. doi:10.1016/j.jacc.2022.11.059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。